All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centersRandomized, controlled Phase IIb trial evaluating TolerogenixX’s proprietary MIC technology, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results